A new theranostic pairing involving 68Ga and 177Lu-NYM096 shows promise in improving the diagnosis and treatment of metastatic clear cell renal cell carcinoma (ccRCC), according to research published in The Journal of Nuclear Medicine. These agents target carbonic anhydrase IX (CAIX), which is overexpressed in ccRCC and can be used for both imaging and therapy. In studies with mice and early human trials, the agents demonstrated high tumor uptake and effective treatment outcomes without significant nephrotoxicity or hepatotoxicity. However, some gastric toxicity was noted, highlighting the need for further evaluation to optimize treatment. Researchers suggest this approach could offer new therapeutic strategies for selected patients with metastatic disease.
Tue, 01 Sep 2026 00:15:35 GMT | Radiology Business